Arthur He CFA Upgrades Vera Therapeutics on Promising Phase 3 Results for Atacicept in IgAN Treatment

H.C. Wainwright analyst Arthur He CFA maintained a Buy rating on Vera Therapeutics (VERA – Research Report) today and set a price target of $85.00.

Arthur He CFA’s rating is based on the promising results from Vera Therapeutics’ Phase 3 ORIGIN study for atacicept, which demonstrated a significant reduction in urine protein creatinine ratio (UPCR) for the treatment of immunoglobulin A nephropathy (IgAN). The study showed a 46% reduction from baseline and a 42% reduction compared to placebo, which is statistically significant and suggests atacicept’s potential as a best-in-class treatment.
Furthermore, the UPCR reduction achieved by atacicept compares favorably to existing IgAN treatments, which have shown reductions ranging from 31% to 38%. This strong performance supports the likelihood of atacicept receiving FDA approval, with Vera planning to file a Biologics License Application (BLA) in the fourth quarter of 2025. Consequently, Arthur He CFA has increased the probability of atacicept’s launch to 90% and raised the price target for VERA to $85, based on a risk-adjusted net present value analysis.

In another report released on May 29, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $100.00 price target.